With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries
découverte viagra TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.
prix du viagra france Insufficient access in remote health settings to simple, accurate and affordable diagnostic tests makes it difficult to provide timely, evidence-based clinical care. Current technology within central laboratories cannot fulfill the existing need in remote health settings, including community level health facilities, remote communities, emergency departments, ICUs and doctors’ offices. The result is millions of preventable deaths from infectious and non-communicable diseases globally, reduced economic growth, and limited human development.
faut il une ordonnance pour acheter du viagra en pharmacie ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing in remote health settings. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016. The company is developing other products that leverage unique attributes of ChipCare’s technology.
medicament le tadalafil Puffin Partners, LP, of Dallas, Texas led the financing round, which includes existing investors MaRS Innovation and Maple Leaf Angels, and new investors, including the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. Angel investors.
viagra hypertension artérielle pulmonaire “ChipCare has the opportunity to bring real value to the diagnostics marketplace, especially for remote health settings,” says Charles E. Gale, Co-Manager of Puffin’s General Partner. “ChipCare’s technology is powerful, flexible and, when implemented, is positioned to make a significant global health impact.”
viagra homme sain “This investment will allow ChipCare to get through clinical trials, regulatory approval and to enter the HIV market allowing people living in remote settings to access life-saving HIV treatment,” says James Fraser, ChipCare’s CEO. “We are grateful to all of our investors to date who are committed to building a profitable and impactful Canadian diagnostics company, and we are eager to make a difference in patient care globally.”
combien coute le viagra generique Prior to this Series A investment, ChipCare raised $3.25 million to develop its platform. Previous investors were led by Grand Challenges Canada, funded by the Government of Canada, which provided $1 million through a Transition to Scale investment and helped catalyze matching investments from a wide range of sources including Maple Leaf Angels, MaRS Innovation, the University of Toronto’s Connaught Seed Fund, the Government of Canada through the National Research Council’s Industrial Research Assistance Program (NRC-IRAP) and the Scientific Research and Experimental Development Tax Incentive Program (SR&ED), and the Government of Ontario through investment by Ontario Centres of Excellence and support by MaRS Discovery District and ventureLAB/Genesis.
l'effet du viagra dure ChipCare’s platform technology was commercialized out of Professor Stewart Aitchison’s research laboratory at the University of Toronto and is led by ChipCare’s multidisciplinary team including James Fraser, James Dou, Rakesh Nayyar and Dr. Lu Chen.
litchi viagra “ChipCare is one of the most promising technologies MaRS Innovation has seen emerging from the University of Toronto’s research community,” says Dr. Raphael Hofstein, President and CEO. “With clear competitive positioning, a strong management team and a solid intellectual property portfolio, ChipCare is well-positioned to succeed in transforming the way we diagnose and treat diseases in the developing world.”
“Ontario’s capacity to compete globally depends on how well we harness our entrepreneurial strengths,” says the Honourable Brad Duguid, Minister of Economic Development, Employment and Infrastructure. “Companies like ChipCare are transforming their discoveries into innovative products, which will help create opportunities abroad, attract investment and help grow our economy.”
“This is a vital new technology for public health,” said Professor Vivek Goel, Vice President, Research and Innovation at the University of Toronto. “HIV/AIDS is still one of the world’s most challenging health issues. The ChipCare technology will have an important impact globally on getting people in remote locations the timely testing and treatment they need. This investment in ChipCare is also a clear indication that the Canadian innovation sector is growing and vibrant.”
ChipCare is a Toronto-based company producing life-saving diagnostics for infectious and non-communicable diseases in remote health settings with a mobile, simple-to-use & lab quality blood-testing platform.
Families in Sweden purchase more drugs per man than any other area. The variety of medicines provided by companies is definitely a contributing aspect to recipe medicine abuse epidemic. Certain medicaments are antifungal medicines. There are variant other medications. If you’re concerned about sexual soundness problem, you probably already know about “coupon for viagra” and “viagra manufacturer coupon“. Often, when people talk about Viagra, they mean “viagra discount coupons“. Questions, like “coupons for viagra“, are linked sundry types of medic problems. However to diagnose a man’s erectile problem, the sex physician likely will begin with a thorough anecdote of indication. Often the treatment options may include erectile dysfunction medicines or counseling. Remember that web-site which is prepared to sell ED drugs like Viagra without a formula is fraudulent. When you buy from an unknown source, you run the risk of getting faked medicines.